Pancreatic enzyme replacement therapy in advanced adenocarcinoma of the pancreas improved overall survival: a retrospective, single institution study
Our findings suggest that treatment of exocrine pancreatic insufficiency (EPI) in advanced PDAC is associated with improvements in nutrition and overall survival.
Authors
- Vincent J. Picozzi
- Jens Kort (ORCID: https://orcid.org/0000-0002-6327-6886)
- Moming Li (ORCID: https://orcid.org/0000-0002-9843-8363)
- Anas Najjar (ORCID: https://orcid.org/0000-0001-7295-2957)
- Margaret T. Mandelson
- Diala Harb
Institutions
- Virginia Mason Medical Center (US)
- AbbVie (United States) (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1093/oncolo/oyaf014
- Citations
- 2
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- AbbVie